|
|
|
|
Medicines/Products by Categories
|
|
|
|
|
|
|
UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE
QUARTER ENDED 31ST MARCH,
2005
|
|
PARTICULARS
|
For the Quarter Ended on 31.03.2005
|
For the Quarter Ended on 31.03.2004
|
For the Year Ended 31.03.2005
|
For the Year Ended 31.03.2004
|
|
|
UNAUDITED
|
REVIEWED
|
UNAUDITED
|
AUDITED
|
|
INCOME FROM OPERATIONS
|
6369.30
|
5845.77
|
24662.24
|
21248.64
|
|
OTHER INCOME
|
60.15
|
114.92
|
1159.21
|
178.89
|
|
TOTAL INCOME
|
6429.45
|
5960.69
|
25821.45
|
21427.53
|
|
TOTAL EXPENDITURE
|
5599.03
|
5312.71
|
21792.86
|
19262.84
|
|
DECREASE IN STOCK IN TRADE
|
-585.31
|
-1247.98
|
1094.47
|
-1884.50
|
|
CONSUMPTION OF RAW MATERIAL
|
5359.84
|
5639.12
|
17359.44
|
18108.87
|
|
COST OF SALES
|
4774.53
|
4391.14
|
18453.91
|
16224.37
|
|
STAFF COST
|
153.61
|
223.93
|
725.89
|
696.55
|
|
OTHER EXPENSES
|
670.89
|
697.64
|
2613.06
|
2341.92
|
|
INTEREST
|
194.72
|
155.31
|
682.68
|
558.71
|
|
DEPRECIATION
|
30.31
|
23.59
|
112.92
|
94.99
|
|
PROFIT BEFORE TAX
|
605.39
|
469.08
|
3232.99
|
1510.99
|
|
PROVISION FOR TAX
|
45.54
|
33.92
|
163.97
|
113.32
|
|
PROVISION FOR DEFERRED TAX
|
82.18
|
23.26
|
257.00
|
100.91
|
|
INCOME TAX FOR THE PREVIOUS YEAR
|
0.00
|
10.75
|
0.00
|
10.75
|
|
NET PROFIT
|
477.67
|
401.15
|
2812.02
|
1286.01
|
|
PAID UP EQUITY SHARE CAPITAL
|
727.57
|
571.57
|
727.57
|
571.57
|
|
RESERVES EXCLUDING REVALUATION RESERVES
|
|
|
|
|
|
EPS - Rs. ANNUALISED
|
7.81
|
7.02
|
45.98
|
23.44
|
| AGGREGATE OF NON-PROMOTERS SHARE
HOLDING |
|
|
|
|
|
NUMBER OF SHARES
|
4758295
|
2939443
|
-
|
-
|
|
% OF SHARE HOLDING
|
65.40
|
63.56
|
-
|
-
|
|
|
NOTES:
|
1) During the financial year
2004-05 the net profit of the company rose by 118.66%
and total turnover rose by 20.51%. During the quarter
under review, the net profit rose by 19% and the income
from operations rose by 9% as compared to the
corresponding quarter of the previous
year.
2) The company has entered into
critical care segments of anesthesiology, oncology and
surgery by creating a dedicated division called
“Resurgence”. The company is also entering herbal
prescription drug by creating super specialty herbal
division to address diseases for which there is no
allopathic cure available. The company also intends to
get into high-value niche segments such as nephrology
and neuropsychiatry and later into the medical devices
segments, especially orthopedic and dental equipments.
The company plan to create total nine marketing
divisions to address different segments and strengthen
its marketing divisions by doubling employees’
strengths.
3) Considering the company’s
strong distributor’s network, it is in process of
forging alliances with originators who are not present
in India and are willing to license their products for
Indian markets (supported by manufacturing strengths of
group company Ind-Swift Laboratories Limited (ISLL) to
supply low cost API) to make and market those products
in India. On other hand company also plans to
out-license its products and NDDS to domestic as well as
global players. The company has forged agreements with
leading domestic companies including Ranbaxy and Lupin
for Nitazoxanide, an anti – diarroheal drug launched for
the first time in India after successful clinical
trails.
4) The company has received a US
patent for New Drug Delivery System (NDDS) of a
macrolide anti-biotic drug. This is the fourth product
from the company stable under NDDS for patient
convenience and compliance, which has earned distinction
for the company. In addition to this, the company has
already filed patents for two of its products based on
NDDS. The R&D of the company is working on
developing 12 new molecules for launching with NDDS,
which are in different stage of R&D. These new
products are from the high growth therapeutic segments
of Cardiology, Diabetology, Neurology, Cancer, Anti –
Asthmatic etc.
5) Continuous introduction
of new API molecules by group company have provided
excellent opportunities to the company in terms of
dosage contract manufacturing along with providing
technical dossier for a speedy launch of their products
to market. This opportunity is available for all
molecules.
6) The company is focusing on
CRAMS as a significant growth driver. The company has
embarked expansion plans which include setting up a
state of the art regulatory compliant dosage form
facility to cater the advanced markets, setting up
another new dosage form facility to cater domestic and
soft regulated market, some acquisitions in health care
sector and an entry into clinical research
operations.
7) The company had received 7
complaints during the quarter under review which were
duly redressed to the satisfaction of the shareholders
during the same quarter and as such, there were no
pending complains as on 31st March, 2005.
8) In the Board meeting held on 31st
March, 2005, 11,60,000 equity shares have been allotted
to the promoter company and outside bodies corporate
upon conversion of equal number of Zero Coupon
Optionally Convertible warrants. Accordingly, the EPS
has been calculated on weighted average basis.
9) The company is exclusively in the
pharmaceutical business segment.
10) The
above financial results were taken on record by the
Board in its meeting held on 30th April, 2005. |
| |
|
By Order of the
Board
|
| |
|
Sd/-
|
| |
|
Dated: 30.04.2005
|
|
(Gopal Munjal)
|
| |
|
Place: Chandigarh
|
|
Chairman
|
|
|